KBR FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages KBR, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action First Filed by the Firm – KBR GlobeNewswire November 07, 2025 NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers […]

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / If you suffered a loss on your KBR, Inc. (NYSE:KBR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kbr-inc-lawsuit-submission-form?prid=176211&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK CITY, NY / ACCESS Newswire / November 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against CarMax, Inc. ("CarMax" or the "Company") (NYSE:KMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form-2?prid=176210&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / If you suffered a loss on your Lantheus Holdings, Inc. (NASDAQ:LNTH) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lantheus-holdings-inc-lawsuit-submission-form-2?prid=176209&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

(NasdaqGM:VERA), Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p<0.0001) If approved, atacicept would be the first B cell modulator targeting both BAFF

NEW YORK CITY, NY / ACCESS Newswire / November 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against CarMax, Inc. ("CarMax" or the "Company") (NYSE:KMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy GlobeNewswire November 07, 2025 Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with

Minneapolis, MN, Nov. 07, 2025 (GLOBE NEWSWIRE) — Carpathian Capital Management (“CCM”) today announced the largest investor distribution in its history. The distribution reflects proceeds from three projects, each executed with CCM's repeatable playbook. “At CCM, process beats prediction,” said Ian Colville, Chief Executive Officer. “While many funds are struggling with post-pandemic distress in the

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / If you suffered a loss on your Savara Inc. (NASDAQ:SVRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/savara-inc-lawsuit-submission-form?prid=176207&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call